Novel Diagnostics for Ocular Structure
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00286637 |
Recruitment Status :
Recruiting
First Posted : February 3, 2006
Last Update Posted : August 24, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Glaucoma Macular Disease |

Study Type : | Observational |
Estimated Enrollment : | 2767 participants |
Observational Model: | Other |
Time Perspective: | Other |
Official Title: | Optical Coherence Tomography Domain Reflectometry & Optical Coherence Tomography Measurements of Intraocular Structure |
Study Start Date : | January 1995 |
Estimated Primary Completion Date : | January 2024 |
Estimated Study Completion Date : | January 2025 |

- Novel Diagnostics for Ocular Structure [ Time Frame: 5 years ]The purpose of this research is to evaluate novel technologies for the assessment of ocular structure and function, including the scanning device called Optical Coherence Tomography (OCT). We will test the OCT and other devices in their ability to image diseases of the eye and also compare the measurements made with OCT to those of other imaging and visual field devices approved by the Food and Drug Administration (FDA). OCT may be useful for the early diagnosis and monitoring of a variety of types of eye diseases

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Age older than or equal to 18 years old
- Macular Degeneration, Diabetic Retinopathy, and/or glaucoma patients.
- Normal control subjects
Exclusion Criteria:
- Media opacity (lens, vitreous, cornea)
- Strabismus, nystagmus, or a condition that would prevent fixation.
- Inability to understand informed consent

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00286637
Contact: Stacy L Mach | 646-501-9883 | Stacy.Mach@nyumc.org |
United States, New York | |
New York University School of Medicine | Recruiting |
New York, New York, United States, 10016 | |
Contact: Stacy L Mach 646-501-9883 Stacy.Mach@nyumc.org | |
Principal Investigator: Joel S Schuman, MD | |
Sub-Investigator: Gadi Wollstein, MD | |
Sub-Investigator: Hiroshi Ishikawa, MD | |
Sub-Investigator: Ian Conner, MD, PhD |
Study Chair: | Joel S Schumann, MD | NYU Langone Health |
Responsible Party: | NYU Langone Health |
ClinicalTrials.gov Identifier: | NCT00286637 |
Other Study ID Numbers: |
R01EY013178-06 ( U.S. NIH Grant/Contract ) R01EY011289-21 ( U.S. NIH Grant/Contract ) P30EY008098 ( U.S. NIH Grant/Contract ) 16-01302 ( Other Identifier: NYUMC IRB ) |
First Posted: | February 3, 2006 Key Record Dates |
Last Update Posted: | August 24, 2020 |
Last Verified: | August 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
OCT CSLO SLP Perimetry electrophysiology |
glaucoma macular degeneration retinopathy diabetes macular hole |
Glaucoma Ocular Hypertension Eye Diseases |